Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 1, 2022

BioPharm International

  • BioPharm International, May 2022 Issue
  • Volume 35
  • Issue 5
  • Pages: 48

High-Capacity Vacuum Filtration Units

Sartorius’ Sartolab RF|BT 150–1000 vacuum filtration units provide fast, high-capacity filtration.

Sartorius’ Sartolab RF|BT 150–1000 vacuum filtration units offer faster and higher capacity filtration relative to past units while also allowing for enhanced physical stability for a wide range of sample types.

The modifications to the product’s design include increased membrane surface area to facilitate optimal filtration, an 0.45 μm polyethersulfone membrane in place of the 0.45 μm cellulose acetate membrane to increase flow rate while keeping the same low-protein binding properties, and an optimized center of gravity to increase stability of the units.

The new units can be directly used on the Sartolab Multistation for parallel filtration. Additionally, the new vacuum filtration units are available in three different pore sizes to meet the needs of most applications: 0.1 μm, 0.22 μm, and 0.45 μm.

Sartorius


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.